FCGR2B and systemic lupus erythematosus: We had previously found in the FcγRIIB−/−Yaa and FcγRIIB−/− lupus models that IRF5 heterozygote mice developed minimal clinical manifestations even though they still expressed approximately 40% as much IRF5 protein as IRF5-sufficient mice [21].